GRCL
Gracell Biotechnologies Inc.
485.20$
-2.8%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Balance Sheet
Gracell Biotechnologies Inc. (GRCL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q3 23), "Total Assets" came in at 1,890 million CNY. Tick rows to compare them in a chart.
All figures in millions of CNY.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q4 18 | Q1 19 | Q2 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37 | 37 | 37 | 103 | 103 | 103 | 412 | – | – | 341 | 965 | 2,388 | 2,292 | 2,197 | 2,060 | 1,933 | 1,899 | 1,838 | 1,656 | 1,474 | 1,378 | 1,890 | |
| 32 | 32 | 32 | 85 | 85 | 85 | 340 | – | – | 216 | 815 | 2,224 | 2,117 | 2,018 | 1,885 | 1,761 | 1,739 | 1,670 | 1,496 | 1,325 | 1,247 | 1,774 | |
| 3.0 | 3.0 | 3.0 | 78 | 78 | 78 | 312 | – | – | 157 | 754 | 2,158 | 2,050 | 1,954 | 1,829 | 1,621 | 1,535 | 1,431 | 1,455 | 1,274 | -158 | 1,677 | |
| – | – | – | – | – | – | 316 | – | – | 177 | 773 | 2,169 | 2,054 | 1,958 | 1,833 | 1,695 | 1,707 | 1,630 | 1,458 | 1,277 | 1,188 | 1,708 | |
| 1.6 | 1.6 | 1.6 | 3.4 | 3.4 | 3.4 | 14 | – | – | 27 | 31 | 31 | – | – | 41 | 41 | 9.9 | – | 26 | 26 | 0.0 | – | |
| – | – | – | – | – | – | 9.4 | – | – | 8.0 | 6.6 | 6.6 | – | – | 8.7 | 8.7 | 22 | – | -26 | -26 | 0.0 | – | |
| – | – | – | – | – | – | 48 | – | – | – | 119 | 144 | 162 | 156 | 153 | 144 | 130 | 150 | 145 | – | – | 109 | |
| 37 | 37 | 37 | 39 | 39 | 39 | 157 | – | – | 77 | 145 | 194 | 219 | 221 | 233 | 261 | 285 | 311 | 281 | 263 | 241 | 269 | |
| 1.9 | 1.9 | 1.9 | 4.5 | 4.5 | 4.5 | 18 | – | – | 32 | 93 | 121 | 132 | 137 | 155 | 187 | 217 | 247 | 221 | 212 | 194 | 229 | |
| 26 | 26 | 26 | 1.1 | 1.1 | 1.1 | – | – | – | 20 | 51 | 77 | 76 | 76 | 86 | 105 | 122 | 147 | 130 | 137 | 115 | 80 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 62 | 62 | – | – | – | – | – | – | |
| – | – | – | – | – | – | 139 | – | – | 45 | 52 | 52 | 56 | 56 | 54 | 54 | 53 | 48 | 47 | 42 | 40 | 34 | |
| – | – | – | – | – | – | 255 | – | – | 264 | 820 | 2,194 | 2,073 | 1,976 | 1,827 | 1,673 | 1,614 | 1,527 | 1,376 | 1,211 | 1,137 | 1,621 | |
| -20 | -20 | -20 | -72 | -72 | -72 | -289 | – | – | -464 | -564 | -664 | -760 | -889 | -1,018 | -1,176 | -1,323 | -1,495 | -1,625 | -1,777 | -1,924 | -1,992 | |
| 37 | 37 | 37 | 37 | 37 | 37 | 4.0 | 4.0 | 4.0 | 13 | 61 | 12 | 13 | 13 | 66 | 14 | 14 | 14 | 68 | 14 | 14 | 17 |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.